Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin‐resistant canine model
Obesity · 2023-07 · 31 (7) · 1798-1811
DOI: 10.1002/oby.23771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 23.05.2023. Verfasst von Morvarid Kabir und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Insulin, Insulin Resistance. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, AstraZeneca, National Institutes of Health.
Abstract (Originalsprache)
Objective
Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) promote urinary glucose excretion, induce weight loss, and reduce fat accumulation. The effects of the SGLT2i dapagliflozin (DAPA) on subcutaneous (SC) and visceral (VIS) adipose tissue function remain unclear. The objective of this study is to evaluate SC and VIS adipose tissue function in an insulin‐resistant canine model.
Methods
A total of 12 dogs were fed a high‐fat diet (HFD) for 6 weeks and then were given a single low dose of streptozotocin (18.5 mg/kg) to induce insulin resistance. Animals were then randomized and exposed to DAPA ( n = 6, 1.25 mg/kg) or placebo ( n = 6) once per day for 6 weeks while remaining on the HFD.
Results
DAPA prevented further weight gain induced by the HFD and normalized fat mass. DAPA reduced fasting glucose and increased free fatty acids, adiponectin, and β‐hydroxybutyrate. DAPA reduced adipocyte diameter and cell distribution. Furthermore, DAPA increased genes associated with beiging, lipolysis, and adiponectin secretion and the expression of the adiponectin receptor ADR2, in SC and VIS adipose tissue. DAPA increased AMP‐activated protein kinase activity and maximal mitochondrial respiratory function, especially in the SC depot. Furthermore, DAPA reduced cytokines and ceramide synthesis enzymes in SC and VIS depots.
Conclusions
For the first time, to our knowledge, we identify mechanisms by which DAPA enhances adipose tissue function in regulating energy homeostasis in an insulin‐resistant canine model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.
- Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Department of Endocrinology, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
ORCID-Profile: Morvarid Kabir, Richard N Bergman, Jay Porter
Förderung
- NIDDK NIH HHS
- AstraZeneca
- National Institutes of Health
Zitieren
APA
Kabir, M., Bergman, R. N., Porter, J., Stefanovski, D., Paszkiewicz, R. L., Piccinini, F., Woolcott, O. O., Yang, H., Gopaul, V. S., Stiles, L., & Kolka, C. M. (2023). Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin‐resistant canine model. Obesity, 31(7), 1798-1811. https://doi.org/10.1002/oby.23771
Vancouver
Kabir M, Bergman RN, Porter J, Stefanovski D, Paszkiewicz RL, Piccinini F, et al. Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin‐resistant canine model. Obesity. 2023;31(7):1798-1811. doi:10.1002/oby.23771
BibTeX
@article{Kabir2023,
author = {Kabir, Morvarid and Bergman, Richard N and Porter, Jay and Stefanovski, Darko and Paszkiewicz, Rebecca L and Piccinini, Francesca and Woolcott, Orison O and Yang, HsiuChiung and Gopaul, V Sashi and Stiles, Linsey and Kolka, Cathryn M},
title = {Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin‐resistant canine model},
journal = {Obesity},
year = {2023},
volume = {31},
number = {7},
pages = {1798--1811},
doi = {10.1002/oby.23771}
}
EUVIMED